Abstract:IMPORTANCE Assessment of additional protection of a booster dose with an inactivated SARS-CoV-2 vaccine is key to developing vaccination strategies for billions of people worldwide who have received the primary 2-dose regimen. OBJECTIVE To estimate the relative effectiveness of a booster dose of an inactivated SARS-CoV-2 vaccine against Omicron infection. DESIGN, SETTING, AND PARTICIPANTS This cohort study was conducted among primary close contacts without previous SARS-CoV-2 infection identified in Shenzhen, China, between February and October 2022. Multiple strict nucleic acid testing and symptom surveillance for SARS-CoV-2 infection were regularly conducted during the 7-day centralized plus 7-day home-based quarantine. EXPOSURE A booster with an inactivated SARS-CoV-2 vaccine vs no booster after receipt of the primary 2-dose inactivated SARS-CoV-2 vaccine regimen. MAIN OUTCOMES AND MEASURES The primary outcomes were overall, symptomatic, and asymptomatic infections. Secondary outcomeswere length of incubation and level of cycle threshold values. All the outcomes were assessed during the quarantine period. RESULTS Among 119 438 eligible participants (mean [SD] age, 37.6 [12.0] years; 66 201 men [55.4%]), 86 251 (72.2%) received a booster dose of an inactivated SARS-CoV-2 vaccine and 33 187 (27.8%) did not. A total of 671 cases infected with Omicron BA.2 were confirmed (464 symptomatic and 207 asymptomatic), and no severe infection or death eventswere observed. At a median (IQR) duration of 111 (75 to 134) days after booster vaccination, the relative effectiveness of a booster was 32.2%(95% CI, 11.3% to 48.2%) for overall infection, 23.8% (95% CI, -8.2% to 46.4%) for symptomatic infection, and 43.3%(95% CI, 12.3% to 63.3%) for asymptomatic infection. The effectiveness against overall infection changed nonlinearly over time following booster vaccination: 44.9%(95% CI, 4.9% to 68.1%) within 60 days, 50.4%(95% CI, 23.7% to 67.7%) at 61 to 120 days, 29.1%(95% CI, -4.8% to 52.1%) at 121 to 180 days, and 19.4%(95% CI, -14.4% to 43.2%) after 180 days (nonlinear P =.03). The effectiveness did not vary significantly according to the interval between booster vaccination and completion of primary vaccination. There was no association of booster vaccination with incubation or cycle threshold values. CONCLUSIONS AND RELEVANCE In this cohort study, a booster dose of an inactivated SARS-CoV-2 vaccine provided additional moderate protection against mild infection for 120 days after receipt, but more research is needed to determine the optimal timing of a booster and its effectiveness in preventing severe infection for a longer duration.

Effectiveness of COVID-19 Vaccination Against SARS-CoV-2 Omicron Variant Infection and Symptoms — China, December 2022–February 2023

Omicron COVID-19 Variant Outcomes and Vaccination in Non-Severe and Non-Critical Patients at Admission

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study

Vaccination Effects on Post-Infection Outcomes in the Omicron BA.2 Outbreak in Shanghai

Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection among Quarantined Close Contacts.

Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study

Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022

The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China

Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021

More Effective Vaccines and Oral Antivirals: Keys for the Battle Against Omicron.

Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai

Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020–2021

Projecting the Impact of the Introduction of SARS-CoV-2 Omicron Variant in China in the Context of Waning Immunity after Vaccination

A Case–case Study on the Effect of Primary and Booster Immunization with China-produced COVID-19 Vaccines on Prevention of Pneumonia and Viral Load among Vaccinated Persons Infected by Delta and Omicron Variants

EPH100 Evaluation of COVID-19 Vaccines in Primary Prevention Against Infections and Reduction in Severity of Illness Following the Outbreak of Sars-Cov-2 Omicron Variant in Shanghai

Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China

The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis

Impact of combination preventative interventions on hospitalization and death under the pandemic of SARS-CoV-2 Omicron variant in China

Effectiveness of Inactivated COVID-19 Vaccines Against SARS-CoV-2 Omicron Subvariant BF.7 among Outpatients in Beijing, China.